高危型HPV16/18感染与前列腺癌的相关性分析

Correlation of high-risk HPV 16/18 infections with prostate cancer

目的:通过检测高危型人乳头瘤病毒(HPV)16/18在前列腺癌(PCa)和良性前列腺增生(BPH)中的表达,探讨HPV16/18与PCa发病之间的相关性,并分析其与临床相关病理参数之间的关系。方法:选取75例PCa和73例BPH组织标本,通过免疫组化和PCR结合反向斑点杂交(RDB)技术,检测HPV16/18的感染情况。结果:免疫组化检测显示,75例PCa标本中16例HPV16/18阳性,阳性率为21.3%;73例BPH标本中7例阳性,阳性率为9.6%,两者比较差异有统计学意义(P=0.049)。PCR结合RDB技术检测显示,75例PCa标本中HPV16阳性17例(22.7%)、HPV18阳性13例(17.3%),其中有4例HPV16/18均阳性;73例BPH标本中HPV16阳性6例(8.2%),HPV18阳性3例(4.1%),无共同阳性例数,两者HPV16/18感染率比较差异有统计学意义(P=0.001)。对比免疫组化和PCR结合RDB 2种方法,两者比较无统计学差异(P=0.069)。HPV16/18感染与PCa临床病理参数中的临床T分期、Gleason评分、临床危险因素等级有一定相关性(P均<0.05),而与年龄、PSA值、有无淋巴结转移等参数无相关性。结论:高危型HPV16/18感染与PCa存在一定的相关性。

Objective： To study the correlation of high-risk human papillomavirus 16 and 18（HPV16 /18） infections with the risk of prostate cancer（ PCa） and their association with the clinicopathologic indexes of PCa. Methods： We collected tissue samples from 75 cases of PCa and 73 cases of benign prostatic hyperplasia（ BPH）. We detected HPV16 /18 infections in the samples by immunohistochemistry and PCR combined with reverse dot blot（ RDB） assay. Results： Immunohistochemistry revealed 16 cases of HPV16 /18 positive in the PCa（21. 3%） and 7 cases in the BPH samples（9. 5%）,with statistically significant difference between the two groups（ P = 0. 049）. PCR combined with RDB assay showed 17 cases of HPV16 infection（22. 6%） and 13 cases of HPV18infection（17. 8%）,including 4 cases of HPV16 /18 positive,in the PCa group,remarkably higher than 6 cases of HPV16 infection（8. 2%）,3 cases of HPV18 infection（4. 1%） and no HPV16 /18 positive in the BPH controls（P = 0. 001）. No significant differences were observed between the result of immunohistochemistry and that of PCR combined with RDB assay（ P = 0. 069）. The risk of HPV16 /18 infections was found to be correlated with the clinical T-stage and Gleason score of PCa（ P〈0. 05） but not with the patient＇s age,PSA level or lymph node metastasis（ P〉0. 05）. Conclusion： High-risk HPV16 /18 infections are correlated with the risk of prostate cancer.